How do you pay?

How to pay the least

Ask for the cash price

Modeyso

We didn’t find one.

  1. Ask your pharmacy for Modeyso’s cash price, and one or two other pharmacies too.
  2. Modeyso’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameModeyso
Authorized genericdordaviprone
Regular genericdordaviprone
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Modeyso?
The original
–
–

Brand nameThe maker’s card

ChimerixCares Copay Assistance

Savings card from Jazz Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on chimerixcares.com 

Or call 1-844-302-2737.

In the maker’s words

“If you have commercial insurance, you may be eligible to pay as little as $0 out of pocket for your prescription.”

From the maker’s offer on chimerixcares.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Modeyso itself, from the same company, sold without the brand name, and usually for less. For now Modeyso is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

MODEYSO is a protease activator indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Source: the FDA label for Modeyso (Jazz Pharmaceuticals, Inc.), January 9, 2026. Full label on DailyMed 

Good to know